|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
PLoS By Category | Recent
PLoS Articles
|
|
Biochemistry - Oncology - Urology
|
Androgen Regulation of 5a-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention
Published:
Wednesday, December 14, 2011
Author:
Jin Li et al.
by Jin Li, Zhiyong Ding, Zhengxin Wang, Jing-Fang Lu, Sankar N. Maity, Nora M. Navone, Christopher J. Logothetis, Gordon B. Mills, Jeri Kim
The enzyme 5a-reductase, which converts testosterone to dihydrotestosterone (DHT), performs key functions in the androgen receptor (AR) signaling pathway. The three isoenzymes of 5a-reductase identified to date are encoded by different genes: SRD5A1, SRD5A2, and SRD5A3. In this study, we investigated mechanisms underlying androgen regulation of 5a-reductase isoenzyme expression in human prostate cells. We found that androgen regulates the mRNA level of 5a-reductase isoenzymes in a cell type–specific manner, that such regulation occurs at the transcriptional level, and that AR is necessary for this regulation. In addition, our results suggest that AR is recruited to a negative androgen response element (nARE) on the promoter of SRD5A3 in vivo and directly binds to the nARE in vitro. The different expression levels of 5a-reductase isoenzymes may confer response or resistance to 5a-reductase inhibitors and thus may have importance in prostate cancer prevention.
More...
|
|
|
 |
|
|
|
|
|
|
|
|